Massive registry aims to uncover hidden risks of blood thinners in heart patients
NCT ID NCT04347187
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This registry is tracking 2,000 people with atrial fibrillation who are taking blood thinners for a long time. The goal is to see how often serious bleeding or clotting events happen. Researchers will also look at genetic factors that might affect risk. This is an observational study, not a treatment trial.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- anticoagulants (blood thinners)
- What this could lead to
- If successful, this registry could help doctors better predict and prevent dangerous bleeding or clotting events in people with atrial fibrillation on long-term blood thinners.
- What could go wrong
- This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patient groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2015
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Hospitalized or outpatients with confirmed atrial fibrillation and CHA2DS2VASC \> 1
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Documented atrial fibrillation with CHA2DS2VASC \> 1 Exclusion Criteria: * Subjects who are unwilling or unable to provide informed consent. ACS within 12 months before inclusion Severe CHF (NYHA IV) Stroke within 6 months before inclusion Severe liver or muscle disease Severe kidney disease / renal failure with creatinine \> 3 mg/dl Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
RECRUITINGMoscow, 121552, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart hole or stroke trigger? global registry tracks who gets closure and what happens next
- Two ways to quiet a racing heart: trial pits hybrid ablation against standard catheter treatment
- Stroke's hidden heart rhythm clue under investigation
- Suture device may get heart patients walking sooner after leg vein procedures
- Two ways to catch a hidden heart rhythm after stroke
- Can an implanted heart monitor catch hidden irregular heartbeats after stroke?